Table 2.
Model characteristics: peer-reviewed articles (19 articles)
| Study, year | Perspective | Country/sponsor | Base-case population | Treatment line | Interventions | Comparators | Analyses type | Model outcomes |
|---|---|---|---|---|---|---|---|---|
| Aceituno et al. (2018) [20] | Public payer | Chile/Tecnofarma S.A. | Adults with RRMM not eligible for transplantation and previously treated | 2L | Rd | Vd | CUA and CEA | Costs, LYs, QALYs, ICER |
| Borg et al. (2016) [54] | Societal | Sweden/Celgene, Kista, Sweden through IHE and BresMed | Adults with previously treated RRMM | 3L+ | Pd | High-dose d | CUA | Costs, LYs, QALYs, ICER |
| Cai et al. (2019) [27] | Payer | USA/Fujian Provincial Department of Science and Technology of the People’s Republic of China and National Natural Science Foundation of China | Adults with previously treated RRMM | 2L+ | Vd |
IRd Rd VTd |
CUA | Costs, QALYs, ICER |
| Campioni et al. (2020) [28] | Payer | Czech Republic/NR | Adults with relapsed MM | 2L+ | KRd | Rd | CUA | Costs, LYs, QALYs, ICER |
| Carlson et al. (2018) [29] | Healthcare payer | USA/Institute for Clinical and Economic Review | Adults with previously treated RRMM | 2L/3L |
Rd IRd ERd KRd PanVd DVd DRd |
NR | CUA | Costs, LYs, QALYs, ICER |
| Dolph et al. (2021) [30] | Commercial payer | USA/Karyopharm Therapeutics | Adults with previously treated RRMM | 2L/3L+ | XVd (low-dose dexamethasone) |
Main: Vd Additional comparators for exploratory analysis: DPd, DRd, Rd, PVd, EPd, KPd, DVd |
CUA and CEA | Costs, LYs, evLYs, QALYs, ICER |
| Gueneau et al. (2018) [55] | NR | France/NR | Adults with RRMM who have received at least 2 prior anti-myeloma therapies | 3L+ | Pd | P | CEA | Costs, LYs, ICER |
| Jakubowiak et al. (2016) [31] | Payer | USA/Amgen | Adults with relapsed MM | 2L+ | KRd | Rd | CUA | Costs, LYs, QALYs, ICER |
| Jakubowiak et al. (2017) [32] | Payer | USA/Amgen | Adults with previously treated RRMM | 2L+ | Kd | Vd | CUA | Costs, LYs, PF LYs, QALYs, ICER |
| Kapinos et al. (2023) [33] | Healthcare payer | USA/none | Adults with triple-class refractory MM | 2L+ | Belamaf |
Ide-cel Cilta-cel |
CUA | QALYs, ICER |
| Karampampa et al. (2023) [56] | Societal | Canada and France/Bristol Myers Squibb | Adults with triple-class exposed MM | 4L+ | Ide-cel | Conventional care | CUA and CEA | Costs, LYs, QALYs, ICER |
| Matsela et al. (2022) [21] | Societal | South Africa/none | Adults with previously treated RRMM | 2L | VRd | d | CUA | Costs, QALYs, ICER |
| Nikolaou et al. (2021) [57] | Commercial payer | USA/GlaxoSmithKline | Adults with RRMM who have received at least 4 prior anti-myeloma therapies | 5L+ | Belamaf | Xd | CUA and CEA | Costs, LYs (PF LY, PP LY), QALYs (PF QALY, PP QALY), ICER |
| Patel et al. (2021) [34] | Payer | USA/American Society of Hematology Physician-Scientist Career Development Award; Frederick A. DeLuca Foundation | Adults with previously treated RRMM | 2L+ | XVd | Vd | CUA | Costs, QALYs, ICER |
| Pelligra et al. (2017) [68] | Payer | USA/Celgene | Adults with heavily pre-treated RRMM | NR | Pd |
D monotherapy K monotherapy |
CUA | Costs, LYs, QALYs, ICER |
| Wong et al. (2021) [35] | Public payer | Singapore/none | Adults with previously treated RRMM | 2L+ | DRd | Rd | CUA | Costs, PF LYs, LYs, QALYs, ICER |
| Zeng et al. (2020) [36] | Payer | USA/none | Adults with previously treated RRMM | 2L+ | DVd | Vd | CUA and CEA | Costs, LYs, QALYs, ICER |
| Zhang et al. (2018) [37] | Healthcare payer | USA/none | Adults with previously treated RRMM | 2L+ |
DVd DRd |
Vd Rd |
CUA | Costs, LYs, QALYs, ICER |
2L second line, 2L+ second line and later, 3L third line, 3L+ third line and late, 4L+ fourth line and later, 5L+ fifth line and later, belamaf belantamab-mafodotin, CEA cost-effectiveness analysis, cilta-cel ciltacabtagene autoleucel, CUA cost-utility analysis, d dexamethasone, DPd daratumumab plus pomalidomide and dexamethasone, DRd daratumumab plus lenalidomide and dexamethasone, DVd daratumumab plus bortezomib and dexamethasone, EPd elotuzumab plus pomalidomide and dexamethasone, ERd elotuzumab plus lenalidomide and dexamethasone, evLY equal value life year, ICER incremental cost-effectiveness ratio, ide-cel idecabtagene vicleucel, IHE The Swedish Institute for Health Economics, IRd ixazomib plus lenalidomide and dexamethasone, KPd carfilzomib plus pomalidomide and dexamethasone, KRd carfilzomib plus lenalidomide and dexamethasone, LY life-year, MM multiple myeloma, NR not reported, P pomalidomide, PanVd panobinostat plus bortezomib and dexamethasone, Pd pomalidomide plus dexamethasone, PF progression free, PP post-progression, PVd pomalidomide plus bortezomib and dexamethasone, QALY quality-adjusted life-year, Rd lenalidomide and dexamethasone, RRMM relapsed/refractory multiple myeloma, V bortezomib, Vd bortezomib and dexamethasone, VTd bortezomib plus thalidomide and dexamethasone, XVd selinexor plus bortezomib and dexamethasone